# A randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment

Published: 28-06-2022
Last updated: 07-04-2024

The purpose of the study is to evaluate how effective rilzabrutinib is and how safe it is, in reducing the signs and symptoms in patients with chronic spontaneous urticaria (CSU), who continue to have symptoms despite the use of H1-antihistamines (...

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Recruiting |
| **Health condition type** | Autoimmune disorders |
| **Study type** | Interventional |

## Summary

### ID

NL-OMON51643

**Source**
ToetsingOnline

**Brief title**
DRI17724

### Condition

- Autoimmune disorders
- Angioedema and urticaria

**Synonym**
chronic spontaneous urticaria

**Research involving**
Human

## Sponsors and support

**Primary sponsor:** Genzyme Europe BV
**Source(s) of monetary or material Support:** Sanofi/ Genzyme B.V.

## Intervention

**Keyword:** CSU, phase 2, Rilzabrutinib

## Outcome measures

### Primary outcome

To demonstrate the efficacy of rilzabrutinib in study participants with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamines (H1-AH)

### Secondary outcome

To demonstrate the efficacy of rilzabrutinib on urticaria activity composite endpoint and itch or hives, separately, at various time points

• To evaluate safety outcome measures

• To assess the plasma PK of rilzabrutinib in participants with CSU

# Study description

### Background summary

A randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment.

This study consists out of a randomization treatment period and an open label treatment period.

### Study objective

The purpose of the study is to evaluate how effective rilzabrutinib is and how safe it is, in reducing the signs and symptoms in patients with chronic spontaneous urticaria (CSU), who continue to have symptoms despite the use of H1-antihistamines (H1AH). This study is conducted in patients, who have never received the medication omalizumab (Xolair®) or who had an incomplete response to omalizumab. Omalizumab is an injectable medication used to treat CSU, asthma and nasal polyps.

### Study design

Fase 2, dubbel blind, randomiseerd, multi-cohort, multi center

### Intervention

- Investigational drugs: SAR444671
- Pharmaceutical form: tablet
- Route of administration: oral

### Study burden and risks

Risks are related to blood withdrawal and possible side effects of the drugs.

## Contacts

**Public**
Genzyme Europe BV

Paasheuvelweg 25
Amsterdam 1105 BP
NL
**Scientific**
Genzyme Europe BV

Paasheuvelweg 25
Amsterdam 1105 BP
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Adults (18-64 years)
Elderly (65 years and older)

## Inclusion criteria

Participants who have a diagnosis of CSU refractory to H1-AH at the time of randomization
- Diagnosis of CSU >=3 months prior to screening visit (Visit 1).
- The presence of itch and hives for >=6 consecutive weeks at any time prior to screening visit (Visit 1) despite the use of H1-AH during this time period.
- Participants using a study defined H1-AH for CSU treatment. For participants on stable doses of non-study-approved H1-AH, investigators may switch participants to an equivalent dose of a study-approved H1-AH maintenance medication.
- Participants who are omalizumab naïve OR omalizumab-incomplete responders.
- Participants must be willing and able to complete a daily symptom e-diary for the duration of the study.
- During the 7 days before randomization: UAS7 >=16 and ISS7 >=8
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

## Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:
- Clearly defined underlying etiology for CUs other than CSU (main manifestation being physical urticaria)
- Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.
- Participants with active atopic dermatitis (AD).
- Severe concomitant illness(es) that, in the Investigator*s judgment, would adversely affect the patient*s participation in the study.

- Known or suspected immunodeficiency, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
- History of serious infections requiring intravenous (IV) therapy with the potential for recurrence (as judged by the Site Investigator and the Sponsor Medical Monitor) with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher), including active coronavirus disease 2019
(COVID-19)
- Live vaccine except Bacille Calmette Guerin-vaccination within 28 days prior to Day 1 or plan to receive one during the trial; Bacille Calmette Guerin-vaccination within 12 months prior to Screening.
- Active malignancy or history of malignancy within 5 years
- Conditions that may predispose the participant to excessive bleeding
- Any participant with an uncontrolled disease state as judged by the Investigator, such as asthma, psoriasis, or inflammatory bowel disease, etc. that are typically treated with oral or parenteral corticosteroids
- Previous use of a BTK inhibitor.
- Has received any investigational drug (or is currently using an investigational device) within the 30 days before Day 1, or at least 5 times the respective elimination half-life time (whichever is longer).
- Previous exposure to another investigative drug for CSU
- Positive for human immunodeficiency virus (HIV) antibody test.
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with positive DNA test result at screening or within 3 months prior to the screening visit.
- Positive hepatitis C antibody test result at screening or within 3 months prior to the screening visit.
- Tuberculosis infection
- Any of significant laboratory abnormalities and ECG findings at the screening visit

# Study design

## Design

| | |
|---|---|
| Study phase: | 2 |
| Study type: | Interventional |
| Intervention model: | Parallel |
| Allocation: | Randomized controlled trial |
| Masking: | Double blinded (masking used) |

| | |
|---|---|
| Control: | Placebo |
| Primary purpose: | Treatment |

### Recruitment

NL

| | |
|---|---|
| Recruitment status: | Recruiting |
| Start date (anticipated): | 22-11-2022 |
| Enrollment: | 9 |
| Type: | Actual |

### Medical products/devices used

| | |
|---|---|
| Product type: | Medicine |
| Brand name: | nog niet bekend |
| Generic name: | Rilzabrutinib |

## Ethics review

| | |
|---|---|
| Approved WMO Date: | 28-06-2022 |
| Application type: | First submission |
| Review commission: | METC NedMec |
| Approved WMO Date: | 24-10-2022 |
| Application type: | First submission |
| Review commission: | METC NedMec |
| Approved WMO Date: | 01-12-2022 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO Date: | 19-12-2022 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO Date: | 20-01-2023 |

| | |
|---|---|
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO Date: | 10-02-2023 |
| Application type: | Amendment |
| Review commission: | METC NedMec |

# Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

| Register | ID |
|---|---|
| EudraCT | EUCTR2021-002609-93-NL |
| CCMO | NL81474.041.22 |
| Other | U1111-1263-4226 |